Stockscreener 앱 받기
1.05
4.55%
-0.05
시간 외 거래:
1.07
0.02
+1.90%
전일 마감가:
$1.10
열려 있는:
$1.1
하루 거래량:
255.47K
Relative Volume:
0.61
시가총액:
$43.57M
수익:
-
순이익/손실:
$-35.58M
주가수익비율:
-0.3962
EPS:
-2.65
순현금흐름:
$-42.82M
1주 성능:
-16.67%
1개월 성능:
-7.08%
6개월 성능:
-18.60%
1년 성능:
-32.26%
1일 변동 폭
$1.05
$1.10
1주일 범위
$1.02
$1.14
52주 변동 폭
$0.808
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
명칭
Iterum Therapeutics Plc
전화
(872) 225-6077
주소
3 DUBLIN LANDINGS, DUBLIN 1
ITRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
1.05 | 43.57M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2021-03-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | 다운그레이드 | Gabelli & Co | Buy → Sell |
| 2019-12-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Iterum Therapeutics Plc 주식(ITRM)의 최신 뉴스
Renaissance Technologies LLC Purchases Shares of 438,816 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Check Out Iterum Therapeutics Plc (ITRM)’s Trade Data Rather Than the Analysts’ Views - Sete News
Iterum Therapeutics Raises $5M from Single Investor: Major Push for Antibiotic Commercialization - Stock Titan
Iterum Therapeutics Plc: Rising -64.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Iterum Therapeutics Plc (ITRM) Becoming More Attractive for Investors - knoxdaily.com
Iterum Therapeutics (ITRM) Secures $5 Million in Direct Offering - GuruFocus
Evaluating ITRM’s financial ratios for a profitable investment - uspostnews.com
Iterum Therapeutics secures $5 million in direct offering - Investing.com
Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares - marketscreener.com
Iterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of Shares - Nasdaq
Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan
ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics - The Manila Times
Groundbreaking Research Reveals Age-Specific Patterns in Antibiotic Resistance for UTI Patients - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
What is Iterum Therapeutics Plc (ITRM) Stock Return on Shareholders’ Capital? - Sete News
Iterum Therapeutics Plc (ITRM): Significant Improvements, Worth Considering - stocksregister.com
Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum - openPR.com
Iterum outlines ORLYNVAH's market potential with exclusivity through 2034 - MSN
Iterum Therapeutics appoints Joseph Whalen to its Board By Investing.com - Investing.com Canada
Iterum Therapeutics appoints Joseph Whalen to its Board - Investing.com
Iterum Therapeutics Appoints New Board Members - TipRanks
Sanctuary Advisors LLC Invests $35,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM) Short Interest Down 5.3% in January - Defense World
Iterum Therapeutics faces Nasdaq non-compliance issue - MSN
A stock that deserves closer examination: Iterum Therapeutics Plc (ITRM) - US Post News
Iterum Therapeutics Plc [ITRM] Insider Activity: An Update for Investors - Knox Daily
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down - MSN
A better buy-in window may exist right now for Iterum Therapeutics Plc (ITRM) - SETE News
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results -February 10, 2025 at 10:41 am EST - Marketscreener.com
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2024 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges Amid ORLYNVAH's Market Debut - GuruFocus
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance
Iterum Therapeutics Highlights FDA Approval and Financial Progress - TipRanks
Earnings call transcript: Iterum Therapeutics reports Q4 2024 results and stock surges - MSN
Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $150 Million -February 07, 2025 at 04:42 pm EST - Marketscreener.com
Iterum Therapeutics Plc’s Shares Reel: 14.34% Quarterly Revenue Decline Amid 40.59M Market Cap - The InvestChronicle
Iterum Therapeutics PLC reports results for the quarter ended December 31Earnings Summary - TradingView
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Iterum Therapeutics plc (ITRM) reports earnings - Quartz
Iterum Therapeutics plc SEC 10-K Report - TradingView
ForexTV | Small Business Resources - ForexTV.com
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Iterum's Landmark UTI Drug ORLYNVAH Powers Financial Turnaround in Q4 Report - StockTitan
Iterum Therapeutics Plc (ITRM) Shares Down Despite Recent Market Volatility - The News Heater
Iterum Therapeutics (ITRM) Expected to Announce Quarterly Earnings on Friday - Defense World
Is Iterum Therapeutics Plc (ITRM) a good investment opportunity? - US Post News
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 - Marketscreener.com
Iterum Therapeutics (NASDAQ:ITRM) Stock Quotes, Forecast and News Summary - Benzinga
Iterum Therapeutics Plc (ITRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):